Podcasts > Archived Podcasts > Industry Focus
This show is no longer producing new episodes. Check out our other shows.
Industry Focus
Healthcare: Is Zolgensma's $2.1 Million Price Tag Ridiculous?
May 29, 2019 (23:14)
Here's why paying $2 million for Novartis' revolutionary gene therapy for SMA may not be as crazy as it sounds.
Also, why shares slumped after BioMarin reported its gene therapy may virtually eliminate bleeding in hemophilia A patients.
Check out more of our content here:
- https://www.fool.com/podcasts/?utm_source=podcasts&utm_medium=podcasts&utm_campaign=industryfocus" rel="noopener" target="_blank">TMF's podcast portal
- https://www.youtube.com/user/TheMotleyFool" rel="noopener" target="_blank">YouTube
- https://twitter.com/mfindustryfocus?lang=en" rel="noopener" target="_blank">Twitter
- https://m.facebook.com/groups/217114601988296">Join Our Motley Fool Podcast Facebook Group
- https://www.linkedin.com/company/the-motley-fool">LinkedIn
- https://www.fool.com/ecap/the_motley_fool/stock-up/?aid=9205&source=isusitsz0000002&ftm_cam=stockup&ftm_veh=sidebarhelp&ftm_mes=signup"> StockUp, The Motley Fool's weekly email newsletter
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.